February 4, 2025 AI Ventures Soar as Trade Tensions Heat Up – Key Weekly Highlights
January 27, 2025 China’s DeepSeek Challenges U.S. AI Giants, Shakes Tech Markets
January 23, 2025 Trump’s AI Revolution: Stargate Initiative Sparks Economic Surge
Tesla: Navigating Challenges Amid Accelerating Innovation Shifts
Nvidia: Unlocking Hidden Catalysts Driving Future Value
Amazon's Q4 Outlook: Navigating Tariffs and Growth Potential
A. O. Smith Corporation: Approaching Value but Risks Persist
Microsoft Demonstrates Resilient Growth Amid Market Challenges
February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024
January 21, 2025 Trading Stocks With AI: A Modern Approach
January 21, 2025 Bitcoin Is Great, but Here Are 3 Altcoins Worth Considering in 2025
January 1, 2025 Advanced Charting Tools For Traders
December 21, 2024 Why Is Trading Important?
Abbott Laboratories (ABT) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: February 6, 2025 (15:08)
Sector: HealthcareThe share price of Abbott Laboratories (ABT) now
News Impact Analyzer
Full report
This Week
|
Na | Impact: Na | News: 1 |
Previous Week
|
Na | Impact: Na | News: Na |
Two Weeks Ago
|
Bearish | Impact: 1.56 | News: 3 (1/0/2) |
Three Weeks Ago
|
Bullish | Impact: 5 | News: 1 (1/0/0) |
Analysts predictions
Full report
This Week
|
Neutral | Opinions: Na |
Previous Week
|
Bullish | Opinions: 2 (2/0/0) |
Two Weeks Ago
|
Neutral | Opinions: Na |
Three Weeks Ago
|
Bullish | Opinions: 1 (1/0/0) |
Analyzing the Most Important ABT news

FDA Warns Diabetes Device Users to Monitor Smartphone Alert Settings


UBS Analyst Warns: One Step Away from a Bubble


Abbott Dips as Q4 Revenue Falls Short

Historical and forecast chart of Abbott Laboratories stock
The chart below shows the historical price of Abbott Laboratories stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Abbott Laboratories stock price can be found in the table below.
Long-term forecasts by years.
Abbott Laboratories Analysts predictions review

Abbott Laboratories (ABT) exhibits a bullish outlook driven by robust core revenue growth in its diagnostics and medical devices segments. Strategic investments in innovation, operational efficiency, and cost management enhance margins and sustain long-term growth potential. Additionally, the company benefits from its diversified product portfolio, mitigating risks and providing revenue stability across economic cycles. Key growth areas include chronic disease care and emerging markets, counterbalancing macroeconomic challenges such as exchange rate volatility and regulatory scrutiny. With easing supply chain pressures and a strong Q4 performance, ABT's valuation offers an attractive entry for long-term investors.

Abbott Laboratories: Solid Q4 Performance Signals Growth Opportunities

Abbott Laboratories has delivered robust Q4 results, demonstrating strong core revenue growth, particularly in its medical devices and diagnostics divisions. The company's ability to capitalize on growing demand for innovative healthcare solutions positions it as a resilient performer in the sector. Such sustained growth in these segments underpins a positive outlook for long-term profitability.
Key Drivers Shaping ABT's Outlook
The author highlights Abbott's consistent focus on innovation and product pipeline expansion, which continue to attract investor confidence. By maintaining a strategy of developing market-leading products, particularly in high-growth categories, the company mitigates risks of market saturation and competitive pressure.
Additionally, Abbott's effective cost management and operational efficiency improvements significantly boost its profitability margins. These efforts underscore management's commitment to creating shareholder value, especially in a competitive macroeconomic environment.
The article focuses on ABT's ability to adapt to changing demographics and the rising demand for chronic disease management solutions. Such strategic alignment with global healthcare trends supports robust, sustainable growth for the company in the foreseeable future.

Abbott Laboratories: Positioned for Growth Amid Renewed Value Opportunity

Abbott Laboratories (ABT) has recently been highlighted as returning to an attractive valuation range, supported by fundamental strengths that signal potential upside for investors. A significant driving factor is the company's diversified healthcare portfolio, which includes market-leading products in diagnostics, medical devices, and nutritional segments. This broad base not only mitigates risks associated with reliance on any single sector but also provides stable revenue streams that can withstand market turbulence. The author underscores this diversification as a critical advantage for ABT's long-term growth trajectory.
Strong Financials and Strategic Positioning
Another key factor is Abbott's consistent financial performance, demonstrated through resilient revenue growth, robust free cash flow generation, and effective cost management. These metrics highlight the company's ability to navigate economic uncertainties, further supporting the stock’s valuation potential. The article also emphasizes Abbott’s strategic investments in innovation, particularly within its medical device and diagnostics segments, which address high-demand areas such as diabetes care and infectious disease testing. These initiatives position the company to capture significant growth in emerging markets and drive future revenue expansion.
Lastly, the upgrade in the stock's rating reflects a broader sentiment shift, likely influenced by improving macroeconomic conditions and easing pressures from supply chain disruptions seen earlier. While short-term headwinds remain in some of its operations, such as the post-pandemic normalization in diagnostics, the core business shows durable strength. The author concludes that ABT's current valuation presents a favorable entry point for long-term investors seeking a stable and growing player in the healthcare sector.

Assessing Abbott Laboratories’ Q4 2024 Growth Catalysts and Earnings Outlook

Abbott Laboratories (ABT) is positioned to deliver strong results in Q4 2024, with significant contributions expected from its core diagnostics and medical device segments. Robust demand for these products, particularly in emerging markets, is expected to underpin revenue growth. Additionally, the company’s strategic focus on innovation has led to new launches in minimally invasive devices and advanced diagnostics, reinforcing its competitive edge.
Key Growth Drivers and Challenges
Operational efficiency continues to enhance Abbott's margins, supported by ongoing cost optimization initiatives and supply chain improvements. However, macroeconomic pressures, including foreign exchange volatility, could partially temper profit growth. While management has indicated confidence in navigating these challenges, currency headwinds remain a notable factor to monitor.
On the downside, the summary highlights potential risks related to regulatory scrutiny in certain international markets. These risks could delay product approvals and introduce compliance costs, slightly dampening the outlook. Nonetheless, the firm’s proven ability to adapt to regulatory environments instills confidence in a longer-term upward trajectory.
Abbott Laboratories' valuation appears elevated, causing potential hesitation among investors in the short term. The author notes that while the company has a strong market position, its current price-to-earnings ratio significantly exceeds historical and sector averages, suggesting limited upside from current levels.
Despite near-term uncertainties, Abbott's diversified product portfolio provides a robust foundation for sustained growth. The author highlights that its exposure to high-growth healthcare segments, such as medical devices and diagnostics, positions the company well to capture long-term demand in these markets.
Analyzing Revenue Trends and Capital Allocation
Recent revenue trends reflect solid performance, but softer growth in certain segments, such as nutrition, may temper overall expectations. However, the firm’s effective capital allocation strategy, including consistent dividend increases, underpins its appeal to income-focused investors.
Macroeconomic factors, including inflation and foreign exchange headwinds, could exert downside pressure on margins. Nevertheless, Abbott's operational resilience and innovation-driven approach may mitigate these risks and support its earnings trajectory over the medium term.
Abbott Laboratories demonstrates robust growth potential driven by its diversified healthcare portfolio, with a notable focus on its Diagnostics and Medical Devices segments. These divisions are poised to benefit from ongoing innovation and increased market adoption, reinforcing the company's ability to generate sustainable revenue growth over the long term.
Balancing Growth Potential and Valuation Metrics
Despite its strong fundamentals, the stock appears fully valued based on its current valuation metrics, as highlighted by the author. This may limit immediate upside potential, particularly in the absence of significant near-term catalysts or unexpected earnings surprises.
Macro-level challenges, such as inflationary pressures and potential interest rate increases, could act as near-term headwinds for operating margins. However, the company's strong balance sheet and operational resilience position it to navigate these challenges effectively over time, mitigating downside risks.
In summary, while the company's growth narrative remains compelling, valuation concerns and macroeconomic uncertainties may temper investor enthusiasm in the near term. Potential buyers may consider adopting a wait-and-watch approach until a more favorable entry point emerges.
Comprehensive Analysis of Abbott Laboratories (ABT) Stock Market Performance
Our multifaceted analysis of Abbott Laboratories's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in Abbott Laboratories stock?
- When should I record a loss on Abbott Laboratories stock?
- What are analysts' forecasts for Abbott Laboratories stock?
- What is the future of Abbott Laboratories stock?
We forecast Abbott Laboratories stock performance using neural networks based on historical data on Abbott Laboratories stocks.
Abbott Laboratories manufactures drugs, medical devices and diagnostic tools – tests for immunity and blood tests that are used in clinics and hospitals in N countries. The first HIV test was developed by Abbott.
Business publications and major stock indices recognize Abbott Laboratories’ contributions: Fortune magazine has ranked the company as one of the most respected in the world every year since 1984.
The company was founded in 1888. The University of Michigan graduate Wallace Abbott worked as a medical practitioner and opened his own pharmacy. He introduced a new way of using alkaloids of medicinal plants: he formed granules from them with micro doses. Treatment with these granules helped patients because the doses of the drug were accurate and the effect was predictable and consistent.
Abbott Laboratories News influencing stock rates

As of now, Panda has combed through 5 news items directly related to ABT from the last 30 days. Out of these, 2 clearly showcase a bullish trend, while 2 display bearish tendencies, and 1 events are neutral.
The strength of the bullish trend outpaces the bearish sentiments by 1.14 times, indicating that the news backdrop is positively influencing the company’s stock price in the current outlook.
The news analyzed fell within the period from Jan 13, 2025, to Feb 05, 2025.
Abbott Shatters Records with Peak Medical Device Sales


Insulet Expands Omnipod 5 Across Europe: Boost for Abbott's CGM Partnership


FDA Draft Guidance: AI's Role in Drug and Device Innovation


Abbott and DexCom Strike a Decade-Long Patent Peace


Abbott Laboratories Boosts Dividend by 7.3%, Signaling Growth


Abbott's Legal Setback: $500M Baby Formula Verdict Stands


Mpox Emergency: WHO's Global Action and Canada's Clade I Case Highlighted


Rising Optimism Signals Growth in Global Healthcare Investments


Insulet's Omnipod 5 Enhances Diabetes Management with Abbott Sensor Integration


First U.S. Mpox Case from Africa Sparks Health Alert


Abbott Laboratories daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Feb 08 | 131.37 | 129.96 | 133.37 | 2.63 |
Feb 09 | 131.11 | 129.93 | 132.97 | 2.34 |
Feb 10 | 128.49 | 126.46 | 129.29 | 2.24 |
Feb 11 | 128.80 | 127.97 | 130.01 | 1.59 |
Feb 12 | 130.50 | 129.90 | 131.36 | 1.13 |
Feb 13 | 129.74 | 127.87 | 131.04 | 2.48 |
Feb 14 | 130.18 | 128.31 | 131.48 | 2.48 |
Feb 15 | 131.41 | 129.96 | 132.19 | 1.72 |
Feb 16 | 129.33 | 127.86 | 130.16 | 1.80 |
Feb 17 | 128.99 | 127.19 | 130.46 | 2.58 |
Feb 18 | 128.56 | 127.01 | 129.30 | 1.80 |
Feb 19 | 130.46 | 129.65 | 131.42 | 1.37 |
Feb 20 | 131.34 | 130.64 | 132.21 | 1.21 |
Feb 21 | 130.58 | 129.88 | 131.50 | 1.25 |
Feb 22 | 129.41 | 128.81 | 130.42 | 1.25 |
Feb 23 | 128.79 | 127.58 | 129.51 | 1.51 |
Feb 24 | 128.74 | 127.47 | 130.33 | 2.24 |
Feb 25 | 127.65 | 126.66 | 129.03 | 1.88 |
Feb 26 | 126.17 | 125.34 | 126.96 | 1.29 |
Feb 27 | 124.84 | 123.24 | 126.01 | 2.25 |
Feb 28 | 124.16 | 122.30 | 124.66 | 1.93 |
Mar 01 | 123.81 | 122.90 | 124.51 | 1.31 |
Mar 02 | 126.29 | 125.56 | 126.85 | 1.03 |
Mar 03 | 127.68 | 126.63 | 128.93 | 1.81 |
Mar 04 | 129.39 | 128.43 | 131.33 | 2.26 |
Mar 05 | 131.12 | 129.31 | 131.88 | 1.99 |
Mar 06 | 131.41 | 130.49 | 132.86 | 1.81 |
Mar 07 | 132.73 | 131.43 | 134.53 | 2.36 |
Mar 08 | 130.55 | 129.35 | 131.20 | 1.43 |
Mar 09 | 128.07 | 126.48 | 128.58 | 1.66 |
Abbott Laboratories Daily Price Targets
Abbott Laboratories Stock Forecast 02-08-2025.
Forecast target price for 02-08-2025: $131.37.
Negative dynamics for Abbott Laboratories shares will prevail with possible volatility of 2.561%.
Pessimistic target level: 129.96
Optimistic target level: 133.37
Abbott Laboratories Stock Forecast 02-09-2025.
Forecast target price for 02-09-2025: $131.11.
Negative dynamics for Abbott Laboratories shares will prevail with possible volatility of 2.288%.
Pessimistic target level: 129.93
Optimistic target level: 132.97
Abbott Laboratories Stock Forecast 02-10-2025.
Forecast target price for 02-10-2025: $128.49.
Negative dynamics for Abbott Laboratories shares will prevail with possible volatility of 2.187%.
Pessimistic target level: 126.46
Optimistic target level: 129.29
Abbott Laboratories Stock Forecast 02-11-2025.
Forecast target price for 02-11-2025: $128.80.
Positive dynamics for Abbott Laboratories shares will prevail with possible volatility of 1.565%.
Pessimistic target level: 127.97
Optimistic target level: 130.01
Abbott Laboratories Stock Forecast 02-12-2025.
Forecast target price for 02-12-2025: $130.50.
Positive dynamics for Abbott Laboratories shares will prevail with possible volatility of 1.113%.
Pessimistic target level: 129.90
Optimistic target level: 131.36
Abbott Laboratories Stock Forecast 02-13-2025.
Forecast target price for 02-13-2025: $129.74.
Negative dynamics for Abbott Laboratories shares will prevail with possible volatility of 2.416%.
Pessimistic target level: 127.87
Optimistic target level: 131.04
ABT (ABT) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Mar. | 127.32 | 120.49 | 133.22 | 9.56 |
Apr. | 124.87 | 119.68 | 128.27 | 6.70 |
May. | 125.27 | 117.66 | 127.48 | 7.70 |
Jun. | 120.56 | 113.04 | 126.35 | 10.53 |
Jul. | 123.07 | 118.44 | 129.96 | 8.86 |
Aug. | 132.82 | 126.87 | 136.96 | 7.37 |
Sep. | 142.70 | 134.14 | 148.29 | 9.55 |
Oct. | 145.21 | 142.54 | 151.71 | 6.05 |
Nov. | 143.81 | 137.49 | 151.29 | 9.13 |
Dec. | 139.67 | 133.08 | 142.24 | 6.44 |
Abbott Laboratories forecast for this year
Abbott Laboratories Stock Prediction for Mar 2025
An downtrend is forecast for this month with an optimal target price of $127.316. Pessimistic: $120.49. Optimistic: $133.22
Abbott Laboratories Stock Prediction for Apr 2025
An downtrend is forecast for this month with an optimal target price of $124.871. Pessimistic: $119.68. Optimistic: $128.27
Abbott Laboratories Stock Prediction for May 2025
An uptrend is forecast for this month with an optimal target price of $125.271. Pessimistic: $117.66. Optimistic: $127.48
Abbott Laboratories Stock Prediction for Jun 2025
An downtrend is forecast for this month with an optimal target price of $120.561. Pessimistic: $113.04. Optimistic: $126.35
Abbott Laboratories Stock Prediction for Jul 2025
An uptrend is forecast for this month with an optimal target price of $123.069. Pessimistic: $118.44. Optimistic: $129.96
Abbott Laboratories Stock Prediction for Aug 2025
An uptrend is forecast for this month with an optimal target price of $132.816. Pessimistic: $126.87. Optimistic: $136.96
Abbott Laboratories Stock Prediction for Sep 2025
An uptrend is forecast for this month with an optimal target price of $142.697. Pessimistic: $134.14. Optimistic: $148.29
Abbott Laboratories Stock Prediction for Oct 2025
An uptrend is forecast for this month with an optimal target price of $145.209. Pessimistic: $142.54. Optimistic: $151.71
Abbott Laboratories Stock Prediction for Nov 2025
An downtrend is forecast for this month with an optimal target price of $143.814. Pessimistic: $137.49. Optimistic: $151.29
Abbott Laboratories Stock Prediction for Dec 2025
An downtrend is forecast for this month with an optimal target price of $139.673. Pessimistic: $133.08. Optimistic: $142.24
Abbott Laboratories (ABT) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 137.77 | 135.46 | 141.08 | 3.98 |
Feb | 132.04 | 127.50 | 137.64 | 7.37 |
Mar | 142.08 | 134.12 | 151.06 | 11.21 |
Apr | 145.15 | 140.27 | 147.47 | 4.88 |
May | 150.14 | 144.25 | 152.66 | 5.51 |
Jun | 153.98 | 147.58 | 160.14 | 7.85 |
Jul | 149.30 | 146.55 | 157.07 | 6.69 |
Aug | 158.62 | 152.15 | 162.68 | 6.47 |
Sep | 169.40 | 165.34 | 180.25 | 8.27 |
Oct | 164.39 | 161.50 | 171.36 | 5.76 |
Nov | 162.94 | 154.99 | 172.20 | 9.99 |
Dec | 158.38 | 154.58 | 165.35 | 6.51 |
Abbott Laboratories (ABT) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 157.75 | 153.33 | 161.66 | 5.15 |
Feb | 165.07 | 155.96 | 174.31 | 10.53 |
Mar | 160.18 | 154.41 | 165.05 | 6.44 |
Apr | 167.87 | 163.44 | 177.14 | 7.73 |
May | 170.56 | 161.55 | 176.70 | 8.57 |
Jun | 168.24 | 159.89 | 178.46 | 10.41 |
Jul | 160.83 | 154.91 | 169.97 | 8.86 |
Aug | 155.94 | 152.95 | 159.19 | 3.92 |
Sep | 157.69 | 152.39 | 163.12 | 6.57 |
Oct | 169.80 | 160.43 | 178.50 | 10.12 |
Nov | 177.00 | 173.32 | 188.05 | 7.83 |
Dec | 184.36 | 176.69 | 193.51 | 8.69 |
Abbott Laboratories information and performance
100 ABBOTT PARK ROAD, ABBOTT PARK, IL, US
Market capitalization of the Abbott Laboratories is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ABT shares in the company outstanding by the market price of one share.
EBITDA of Abbott Laboratories is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Abbott Laboratories (ABT) stock dividend
Abbott Laboratories last paid dividends on 01/15/2025. The next scheduled payment will be on 02/14/2025. The amount of dividends is $0 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
FAQ (Frequently Asked Questions about Abbott Laboratories Stock)
Should I Buy Abbott Laboratories Shares in 2025 year?
Does Abbott Laboratories pay dividends?
Which economic sector do Abbott Laboratories's shares belong to?
Which other securities belong to the same sector as Abbott Laboratories's shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.